The Coalition for Epidemic Preparedness Innovation (CEPI) said on Tuesday it will fund the development of the protein-based S-Trimer Covid-19 vaccine candidate by China’s Clover Biopharmaceuticals Inc.
CEPI’s total investment in S-Trimer will be up to $328 million, it said in a statement.
The funding will happen through to licensure, including a global phase 2/3 efficacy clinical study beginning before the end of 2020, the statement added.
Oslo, Norway-based CEPI was set up in 2017 to fight emerging epidemics and is backed by 14 governments, the Bill and Melinda Gates Foundation and Britain’s Wellcome Trust.
The extension of CEPI’s partnership with Clover comes months after it invested $66 million to boost the Chinese company’s Covid-19 vaccine trial in July.
ALSO READBharat Biotech to launch Covaxin in Q2 2021
The deal between Clover and CEPI anticipates that the vaccine, if proven safe and effective, will be made available for procurement and allocation through the Covax facility around the world.
The World Health Organization-backed Covax programme aims to deliver at least 2 billion doses of vaccine by the end of 2021. It is co-led by the GAVI vaccines alliance, the WHO and the CEPI.
CEPI has previously deployed vast sums of money in search of a Covid-19 vaccine through partnerships with drug developers including Inovio Pharmaceuticals Inc, Moderna Inc , and Novavax Inc.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.